comparemela.com

Latest Breaking News On - Flughafen wien group - Page 5 : comparemela.com

21st Austria weekly - DO & CO, Vienna Airport, Strabag (16/11/2023)

21st Austria weekly - DO & CO Vienna Airport Strabag 16/11/2023 [pic1]DO & CO: Catering company CO benefited from increased demand in all divisions Airline Events Restaurants and with sales of € 880.11m PY: 667.16m achieved the strongest half year terms revenue Company’s history. This constitutes an increase 31.9% or 212.95m as compared to same period previous year. The EBITDA Group was 95.85m 67.48m first business 2023/2024. net result more than doubled 14.04m 35.48m. All are experiencing continued high demand stated its outlook and emphasizes: "Due

September 2023 Traffic Results: 3,801,022 passengers handled by the Flughafen Wien Group and 2,919,579 by Vienna Airport – Passenger volume in September 2023 only slightly below the pre-crisis levelmore details -October 12, 2023 at 01:35 am EDT

September 2023 Traffic Results: 3,801,022 passengers handled by the Flughafen Wien Group and 2,919,579 by Vienna Airport - Passenger volume in September 2023 only slightly below the pre-crisis level .

August 2023 Traffic Results: 4,084,286 passengers handled by the Flughafen Wien Group and 3,103,842 by Vienna Airport – Passenger volume almost at the pre-crisis level in the holiday month of Augustmore details -Today at 01:34 am

August 2023 Traffic Results: 4,084,286 passengers handled by the Flughafen Wien Group and 3,103,842 by Vienna Airport - Passenger volume almost at the pre-crisis level in the holiday month of August .

21st Austria weekly - Marinomed, Vienna Airport, Kapsch TrafficCom, Andritz, Valneva, Addiko (17/08/2023)

21st Austria weekly - Marinomed Vienna Airport Kapsch TrafficCom Andritz Valneva Addiko 17/08/2023 [pic1]Marinomed: Marinomed Biotech AG reported a rise of revenues for the first half 2023 +7% to € 5.2 million after 4.9 in H1 2022 driven by continued strong demand Carragelose products. The operating result period was -2.9 H1 2022: -2.5 million due increased R&D expenses and personnel costs. successful obtaining market authorization Mexico as well expansion portfolio with an eye drop product anti-allergic next season 2024. Supported excellent clinical data its two Marinosolv-based candidates Tacrosolv Budesolv company pushed business development activities aim enter new partnership end year. also entered long-term Solv4U dynamic Chinese

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.